Q3 EPS Estimates for Compass Therapeutics Lowered by Wedbush

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Wedbush cut their Q3 2025 earnings per share estimates for shares of Compass Therapeutics in a report issued on Tuesday, April 1st. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.13) for the quarter, down from their previous forecast of ($0.10). Wedbush has a “Outperform” rating and a $8.00 price objective on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Compass Therapeutics’ Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.42 EPS.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01).

A number of other brokerages also recently commented on CMPX. Piper Sandler assumed coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price objective for the company. HC Wainwright boosted their price target on Compass Therapeutics from $10.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday. Guggenheim restated a “buy” rating and set a $12.00 price objective on shares of Compass Therapeutics in a research note on Wednesday. Leerink Partnrs upgraded Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Finally, Jefferies Financial Group increased their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $13.38.

Compass Therapeutics Stock Performance

NASDAQ CMPX opened at $1.46 on Friday. The company’s 50-day simple moving average is $2.76 and its two-hundred day simple moving average is $2.10. Compass Therapeutics has a one year low of $0.77 and a one year high of $4.08. The company has a market capitalization of $201.89 million, a price-to-earnings ratio of -3.95 and a beta of 1.19.

Institutional Investors Weigh In On Compass Therapeutics

A number of large investors have recently bought and sold shares of the company. Intech Investment Management LLC acquired a new stake in Compass Therapeutics during the 3rd quarter worth about $30,000. Tower Research Capital LLC TRC raised its holdings in Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after purchasing an additional 12,917 shares during the period. Independent Advisor Alliance purchased a new position in Compass Therapeutics during the fourth quarter worth approximately $26,000. BNP Paribas Financial Markets acquired a new stake in Compass Therapeutics in the fourth quarter valued at approximately $27,000. Finally, XTX Topco Ltd purchased a new stake in shares of Compass Therapeutics in the third quarter valued at approximately $37,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.